• Shire plc, of Dublin, said Intuniv XR (guanfacine hydrochloride extended-release tablets) is now available in Canada for the treatment of attention deficit hyperactivity disorder in children ages 6 to 12.
“It’s nice to make money with people you like,” said Antoine Papiernik, managing partner at Sofinnova Partners, about the $200 million-up-front deal engineered between Clovis Oncology Inc. and Ethical Oncology Science SpA (EOS).
With its latest $110 million financing, Moderna Therapeutics Inc. is rapidly closing on the half-billion-dollar mark in terms of funds raised for the 2-year-old company. The new funds bring the company’s total funds raised to $415 million, and it will end the year with about $340 million in the bank.
Vertex Pharmaceuticals Inc. isn’t above using a good trick twice. Back in 2008, the Cambridge, Mass.-based firm picked up $160 million by selling royalty rights to two Glaxosmithkline plc-marketed drugs to help push through late-stage testing with then-game-changing hepatitis C virus (HCV) drug telaprevir.
• Biocardia Inc., of San Carlos, Calif., reported 12-month results for the Phase II Transendocardial Autologous Cells (mesenchymal cells, or MSC, or bone marrow mononuclear cells, or BMC) in Ischemic Heart Failure Trial (TAC-HFT).
• Simcere Pharmaceutical Group, of Nanjing, China, said it called an extraordinary general meeting for Dec. 19 to consider and vote on, among other items, the proposal to approve the plan of merger dated Aug. 28, 2013, between Simcere Holding Ltd. and Simcere Acquisition Ltd.
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported clinical results from a study of 145 healthy male volunteers showing that its fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran, with onset of action detected immediately following a five-minute infusion.
• Oxford Biomedica plc, of Oxford, UK, signed a loan facility agreement for £5 million (US$8 million) secured loan facility agreement with Vulpes Life Sciences Fund, its largest shareholder.
RSS